(Q60629643)

English

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial

scientific article published on 06 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Jean-Pierre Pignon

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Michel Ducreux

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

David Malka

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jean Mendiboure

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Pierre-Luc Etienne

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Patrick Texereau

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Dominique Auby

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Philippe Rougier

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Mohamed Gasmi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Marine Castaing

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Moncef Abbas

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Pierre Michel

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Dany Gargot

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ahmed Azzedine

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Catherine Lombard-Bohas

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Patrick Geoffroy

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Bernard Denis

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Laurent Bedenne

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Olivier Bouché

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

6 September 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1032-1044

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New options and old dilemmas in the treatment of patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970199-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70199-1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21903473%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q60629643&oldid=2134322509"